Cryoport enters into strategic relationship with takeda's biolife plasma services

Cryoport plans to establish an integrated supply chain platform with biolife plasma services to offer standardized cell therapy collection, processing, and storage services in united states and europe over time nashville, tenn. , sept. 8, 2022 /prnewswire/ -- cryoport, inc.  (nasdaq: cyrx) ("cryoport" or the "company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced it has entered into a strategic relationship with biolife plasma services, part of the global biopharmaceutical company takeda, intended to provide consistent, high-quality cellular starting material for use in the manufacture of life-saving cellular therapies.
CYRX Ratings Summary
CYRX Quant Ranking